Sol-Gel Technologies Ltd. logo
Sol-Gel Technologies Ltd. SLGL
$ 72.97 -10.7%

Annual report 2025
added 03-21-2026

report update icon

Sol-Gel Technologies Ltd. Financial Ratios 2011-2026 | SLGL

Annual Financial Ratios Sol-Gel Technologies Ltd.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-33.2 -1.2 -1.0 -4.3 49.9 -7.5 -10.2 -3.3 -0.5 - - - - - -

P/S

- - - - 5.1 25.0 10.9 829.7 99.4 - - - - - -

EPS

-2.2 -0.4 -1.0 -0.7 0.1 -1.3 -1.3 1.8 5.0 3.3 1.5 - - - -

EV (Enterprise Value)

- - - - 154 M 221 M 250 M 107 M 80.3 M 35.3 M 19.8 M - - - -

EBITDA per Share

- - - - 0.17 -1.3 -1.28 -1.83 -4.95 - - - - - -

EV/EBITDA

34.3 -7.3 -9.8 -3.1 - - - - - - -

PEG

- 2.36 -0.34 1.3 - - - - - - -

P/B

8.9 0.5 0.7 1.5 2.9 4.3 4.8 1.7 -0.3 - - - - - -

P/CF

631.3 -0.9 -1.5 -6.7 -20.9 -8.7 -11.1 -4.6 -0.7 - - - - - -

ROE %

-26.86 -36.67 -70.48 -35.35 5.79 -57.60 -46.91 -50.39 59.90 - - - - - -

ROA %

-20.48 -29.52 -60.15 -32.00 4.66 -49.51 -40.14 -46.21 -206.12 - - - - - -

ROCE %

-31.74 -39.31 -71.89 -37.52 5.16 -56.83 -47.36 -51.74 60.96 - - - - - -

Current Ratio

4.2 5.1 6.8 10.6 5.1 7.1 6.9 12.1 0.2 - - - - - -

DSO

- - - - 88.8 130.5 32.8 - - - - - - - -

Operating Cycle

- - - - 88.8 130.5 32.8 - - - - - - - -

Cash Conversion Cycle

- - - - 88.8 130.5 32.8 - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Sol-Gel Technologies Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- - - - - - 0.35 - - - 0.31 - - - 0.26 - - - 0.36 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - - - - - -0.35 - - - -0.33 - - - -0.28 - - - -0.38 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

- - -20.47 -40.94 -40.94 -20.47 -31.26 -21.58 -21.58 -10.79 -19.79 -18.00 -18.00 -9.00 -17.47 -16.94 -16.94 -8.47 -8.47 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

- - -17.31 -34.62 -34.62 -17.31 -26.78 -18.95 -18.95 -9.47 -17.25 -15.54 -15.54 -7.77 -7.77 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

- - -19.50 -38.99 -38.99 -19.50 -30.65 -22.30 -22.30 -11.15 -20.58 -18.87 -18.87 -9.43 -18.37 -17.87 -17.87 -8.93 -8.93 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

- - - - 5.1 - 6.5 - 7.1 - 8.2 - 6.9 - 7.3 - 12.1 - - - 0.2 - - - 0.3 - - - - - - - - - - - - - - - - - - - - - - -

DSO

- - - - - - 47.0 - - - 47.2 - - - 45.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - - - 47.0 - - - 47.2 - - - 45.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - - - - - 47.0 - - - 47.2 - - - 45.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Sol-Gel Technologies Ltd., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.88 -0.87 % $ 5 B danmarkDanmark
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 15.36 -0.71 % $ 7.59 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Inventiva S.A. Inventiva S.A.
IVA
$ 5.78 -4.3 % $ 138 M franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.21 -3.97 % $ 71.5 M britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 2.28 -0.44 % $ 1.03 M israelIsrael
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Assembly Biosciences Assembly Biosciences
ASMB
$ 28.46 3.45 % $ 319 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.37 -4.2 % $ 350 M britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 156.92 -1.23 % $ 7.81 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.4 -3.68 % $ 1.02 B canadaCanada
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.13 -1.64 % $ 10.4 B usaUSA
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.98 -4.52 % $ 452 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.09 -0.95 % $ 195 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.52 -5.59 % $ 178 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 7.7 -5.87 % $ 1.29 B britainBritain
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.6 -3.8 % $ 115 M usaUSA
Curis Curis
CRIS
$ 0.77 1.89 % $ 4.86 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.34 -4.02 % $ 116 M franceFrance